Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Philogen SpA ( (IT:PHIL) ) has shared an announcement.
Philogen S.p.A., the Italian-Swiss biotech group specializing in targeted anti-tumor therapies, has detailed the structure of its share capital ahead of its shareholders’ meeting scheduled for 29 April 2026. The company leverages proprietary ligand-discovery technologies and a vascular targeting approach to develop novel drugs for high-mortality diseases.
The company disclosed that its share capital consists of 40,611,111 shares, corresponding to a total of 63,347,611 voting rights. This includes 29,242,861 ordinary shares with one vote each and 11,368,250 class B multiple-vote shares carrying 34,104,750 votes, underscoring a capital structure that concentrates enhanced voting power in the multiple-vote share class ahead of key corporate decisions.
The most recent analyst rating on (IT:PHIL) stock is a Hold with a EUR18.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
More about Philogen SpA
Philogen S.p.A. is an Italian-Swiss biotechnology group focused on researching and developing pharmaceutical products for diseases with high mortality rates, primarily in oncology. The company develops targeted anti-tumor drugs using high-affinity ligands, such as human monoclonal antibodies and small organic molecules, identified through proprietary Antibody Phage Display and DNA-Encoded Chemical Library technologies.
Its core strategy, known as tumor targeting, delivers potent therapeutic agents like pro-inflammatory cytokines directly to tumor tissue while sparing healthy cells. Philogen has pioneered vascular targeting, creating ligands for antigens expressed on tumor-associated blood vessels, and aims to commercialize innovative treatments for conditions lacking effective therapies, with potential applications also in chronic inflammatory diseases.
YTD Price Performance: -10.52%
Average Trading Volume: 19,138
Technical Sentiment Signal: Hold
Current Market Cap: €609.7M
Learn more about PHIL stock on TipRanks’ Stock Analysis page.